bioAffinity's CyPath® Lung Sales Surge 300% YoY in April 2026
Event summary
- CyPath® Lung unit sales hit record high in April 2026, up 300% YoY.
- Sales growth outpaces internal projections, driven by physician adoption.
- Test helps detect early-stage lung cancer with 92% sensitivity and 99% NPV.
- Company focuses commercial strategy on expanding ordering physician sites.
The big picture
The surge in CyPath® Lung sales reflects growing physician demand for noninvasive early cancer detection tools amid rising pulmonary nodule cases. This aligns with broader industry trends toward precision diagnostics and risk stratification in oncology. The company's focused commercial strategy positions it to capitalize on expanding clinical use, though regulatory and reimbursement dynamics remain critical factors.
What we're watching
- Adoption Pace
- Whether bioAffinity can sustain this rapid adoption rate beyond high-growth months.
- Regulatory Dynamics
- How CMS oversight of LDTs may impact CyPath® Lung's market position.
- Pipeline Expansion
- The pace at which bioAffinity advances its R&D pipeline for asthma and COPD diagnostics.
Related topics